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Treatment of vaso-occlusive pain related to sickle cell disease in  
pediatric patients: A systematic review 
 
Rebecca Tourtellotte1 PharmD Candidate, Kristina E. Ward1 BS, PharmD, BCPS 
 
1The University of Rhode Island, College of Pharmacy 
   
Sickle cell disease (SCD) is a rare inherited disorder that affects the shape of erythrocytes. 
SCD is estimated to affect 70,000 - 100,000 Americans and is seen predominately in 
African-Americans.1 In SCD, the body produces sickle-shaped red blood cells, which have 
shorter lifespans than normal red blood cells and can lead to anemia. The abnormal shape 
causes them to become lodged in blood vessels, causing pain and organ damage. Symptoms 
generally begin by three years of age and complications of sickle cell disease include vaso-
occlusive crises, acute chest syndrome, and others.2 A vaso-occlusive crisis is an episode of 
pain, described as sharp, intense, and throbbing, most commonly occurring in the lower 
back, leg, hip, abdomen, or chest. It typically begins at night and lasts 3-14 days. It is the 
most common reason for hospitalization in patients with SCD.3 Episodes increase in 
frequency throughout childhood.4 No cure for SCD is widely available; treatment is 
symptomatic and supportive. No evidence based guidelines for the treatment of pain during 
vaso-occlusive crises in pediatric patients with SCD are published.3 
 
 
 
 
The purpose of this literature review was to evaluate the safety and efficacy data of selected 
trials, provide a summary of evidence-based treatments, and identify specific areas where 
more studies are needed in the treatment of vaso-occlusive crises in pediatric patients. 
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INTRODUCTION 
METHODOLOGY 
Studies were included in the review if they were randomized controlled trials. Trials must 
include participants 18 years and younger with sickle cell disease. The intervention must be 
an FDA approved medication (not necessarily approved for SCD). One of the outcomes 
measured in the trial must be reduction in pain score; no standard pain score exists so 
different scores will be included (Wong-Baker FACES Pain Rating Scale, Visual Analog 
Scale, etc. See Figure 1 and Figure 2).  Secondary outcomes include serious adverse events. 
Studies were evaluated for rigor using the JADAD score, and were included if the score was 
≥ 3.  
  
Literature searches were conducted using PubMed, Embase, Cochrane Central Register, 
and ClinicalTrials.gov. Search terms included (but were not limited to): “sickle cell 
disease”, “sickle cell crisis”, “vaso-occlusive crisis”, “pain management”, “analgesia”, 
“opioid”, “non-opioid”, “NSAID”, “pediatric”, and “children”. 
RESULTS  
• A comprehensive literature search provided 1,094 results, including duplicate results 
• Screening of the literature search results identified 16 trials that needed further evaluation 
• Six trials were included in the systematic review, after application of the inclusion and exclusion 
criteria. Studies are summarized in Figure 3 and Table 1. 
• Many studies were excluded resulting from lack of rigor in study design or missing results.  
Of the six studies analyzed, two showed statistical significance in the decrease in pain scores 
in children with vaso-occlusive crises. The Fein trial showed a significant reduction in pain 
score at 20 minutes after the administration of intranasal fentanyl.  The difference was seen 
at 20 minutes after administration, but not 10 or 30 minutes. The Morris trial showed a 
significant difference in pain scores at discharge in patients in the arginine arm. The other 
studies did not show statistical significance, however the small sample size of the trials only 
had the power to detect large changes in outcomes. Another consideration is the difference 
between clinical significance and statistical significance. While the trials may not have had 
a statistical difference in pain scores, the differences may have been enough to show clinical 
improvements in patients. No serious adverse effects were seen in any of the trials.  
A strength of this study is limited inclusion criteria to allow for as many trials to be 
included as possible. The literature search was comprehensive and complete. Weaknesses 
include the small sample sizes in trials, differences in pain scales used, and differences in 
the time periods in which pain was measured during the crisis. Each trial measured pain 
scores at different points throughout treatment, and it is difficult to compare and 
generalize the different results. Limited published trials exist that are controlled clinical 
trials with strong designs. 
 
Table 1.  Summary of included trials 
Six trials were reviewed for safety and efficacy data. 
REFERENCES 
CONCLUSIONS 
Based on the results of the literature review, intranasal fentanyl and L-arginine have some 
evidence for use in pediatric patients with vaso-occlusive crises. More evidence is needed; 
however both may be reasonable, safe options in patients with uncontrolled pain as an 
adjunct to standard therapy. 
   
Trials are needed with larger sample sizes to detect a smaller change in outcomes. It would 
be beneficial if trials used a standard pain scale, easing the comparison between trials. 
Studies in this population are difficult because of the subjectivity of endpoints, such as pain 
and length of stay. Length of stay may be influenced by many non-treatment related factors 
(e.g. discharge paper work), although it was included in many of the reviewed trials as a 
primary or secondary outcome. Future reviews may evaluate the efficacy of medication for 
vaso-occlusive crises based on different outcome measures. The ethical concerns of 
studying medications in children, the lack of incentives for studying rare diseases, and 
the subjectivity of pain make studying the management of vaso-occlusive crises in 
pediatric patients very difficult, however this review provides information regarding 
safe and effective, evidence-based treatments for pediatric patients with vaso-
occlusive pain. 
PURPOSE 
Name of trial Pain Scale Outcome Measure Results Safety 
Fein, et al.6 Wong-Baker 
FACES 
Median reduction in 
pain score 20 minutes 
after drug 
administration 
Pain score was reduced by 2 
in the IN fentanyl group vs. 
1 in the placebo group 
(p=0.048) 20 minutes after 
drug administration. No 
significant difference was 
seen at 10 or 30 minutes 
No significant 
difference in 
serious adverse 
effects 
Gladwin, et al.7 Visual Analog 
Scale 
Pain score at 24 hours, 
and change from 
baseline at 2, 4, 6, and 
8 hours 
The difference in mean VAS 
scores at 24 hours or the 
change from baseline was 
not significant between 
groups. 
No significant 
difference in 
serious adverse 
effects 
Weiner, et al. 8 Visual Analog 
Scale 
Difference in pain 
scores at 4 hours from 
baseline 
The difference in pain 
scores at 4 hours was not 
statistically significant 
between the two groups. 
No serious 
adverse events 
were seen in 
either group 
Goldman, et al.9 Faces Pain Scale 
– Revised, 
Visual Analog 
Scale 
Mean pain score The difference in mean and 
median pain scores was not 
significant between the two 
groups. 
Infusion site 
reactions were 
more common in 
IV MgSO4 group 
Hardwick, et al.10 Visual Analog 
Scale 
Reduction in pain 
severity (VAS score) 
The reduction in pain 
severity did not differ 
significantly between the 
two groups. 
No significant 
difference in 
serious adverse 
events 
Morris, et al.11 Visual Analog 
Scale, Faces 
Pain Scale 
Pain scores at 
discharge 
There was a significant 
difference in pain scores at 
discharge (1.9 L-arginine vs. 
3.9 placebo, p < 0.001) 
No drug-related 
adverse events in 
either group 
Fein, et al. 
Intranasal 
fentanyl 
n = 49 
Gladwin, 
et al. 
Inhaled 
nitric oxide 
n = 150  
Weiner, et 
al. 
Inhaled 
nitric oxide 
n = 20 
Goldman, 
et al. 
Magnesium 
sulfate 
n = 104 
Hardwick, 
et al. 
Ketorolac 
n = 41 
Morris, et 
al. 
L-arginine 
n = 54 
 
Figure 3.  Summary of included trials 
Includes intervention studied and sample size 
 
Figure 1.  Wong-Baker FACES Pain Rating Scale 
Recommended for children three years and older. Child is asked to choose the 
face that best describes his/her own pain.5 
 
Figure 2.  Visual Analog Scale 
Patients are asked to rate pain on a 
10 cm line and the distance from no 
pain is considered the pain score.5 
